Pacific Biosciences of California, Inc. (PACB) Financial Statements
Industry: Laboratory Analytical Instruments
In fiscal 2025, Pacific Biosciences of California reported revenue of $160.0M, up 3.9% from $154.0M the year before. Net income was -$546.4M (a -341.5% net margin), or -$1.82 per diluted share. Gross margin was 28.6% and operating margin was -346.2%. Operating activities generated -$111.2M of cash, leaving -$113.9M of free cash flow. At fiscal year end, Pacific Biosciences of California held $784.1M in total assets against $778.7M in total liabilities, including $63.7M of cash and equivalents.
Open the full interactive Pacific Biosciences of California financials → Quarterly statements, key ratios, valuation history and price charts.
Pacific Biosciences of California Key Stats
| Share Price | $2.05 |
|---|---|
| Market Cap | $636.8M |
| Revenue YoY Growth | +3.9% |
| 52-Week Range | $1.11 – $2.87 |
| Shares Outstanding | 310.7 million (basic, 2026 Q2) |
Pacific Biosciences of California Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $78.9M | $130.5M | $128.3M | $200.5M | $154.0M | $160.0M |
| Cost of Goods Sold | $46.3M | $56.4M | $79.3M | — | — | — |
| Gross Profit | $32.6M | $58.9M | $49.0M | $52.8M | $37.3M | $45.8M |
| Operating Income | -$104.4M | -$210.4M | -$307.2M | -$334.5M | -$474.3M | -$553.9M |
| Pre-Tax Income | $29.5M | -$274.9M | -$314.2M | -$318.2M | -$309.5M | -$546.1M |
| Income Tax | $97,000 | -$93.6M | — | -$11.4M | $316,000 | $318,000 |
| Net Income | $29.4M | -$181.2M | -$314.2M | -$306.7M | -$309.9M | -$546.4M |
| Diluted EPS | $0.17 | -$0.89 | -$1.40 | -$1.21 | -$1.59 | -$1.82 |
Pacific Biosciences of California Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $38.4M | $44.6M | $37.2M | $39.0M |
| Net Income | -$38.0M | -$40.4M | -$8.3M | -$44.7M |
| Diluted EPS | -$0.13 | -$0.13 | -$0.03 | -$0.14 |
Pacific Biosciences of California Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $81.6M | $460.7M | $325.1M | $179.9M | $55.4M | $63.7M |
| Current Assets | $355.6M | $1.10B | $852.1M | $742.0M | $495.7M | $375.1M |
| Total Assets | $414.0M | $2.01B | $1.77B | $1.75B | $1.26B | $784.1M |
| Current Liabilities | $38.5M | $71.7M | $263.3M | $95.0M | $66.3M | $72.8M |
| Total Long-Term Debt | — | $896.1M | $896.7M | $892.7M | $647.5M | $645.4M |
| Total Liabilities | $78.5M | $1.22B | $1.20B | $1.04B | $753.9M | $778.7M |
| Shareholders' Equity | $335.5M | $791.0M | $562.9M | $701.3M | $506.6M | $5.3M |
Pacific Biosciences of California Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $19.5M | -$111.2M | -$263.2M | -$259.2M | -$206.1M | -$111.2M |
| Cash From Investing | -$219.3M | -$678.5M | $116.1M | $4.6M | $124.0M | $115.4M |
| Cash From Financing | $251.8M | $1.17B | $9.6M | $108.9M | -$43.0M | $3.4M |
| Free Cash Flow | $18.5M | -$117.1M | -$280.0M | -$268.0M | -$212.2M | -$113.9M |
Figures from Pacific Biosciences of California's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pacific Biosciences of California financials page for every line item.
Pacific Biosciences of California Company Profile
| Ticker | PACB |
|---|---|
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Headquarters | Menlo Park, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001299130 |
Frequently Asked Questions
What was Pacific Biosciences of California's revenue in fiscal 2025?
Pacific Biosciences of California (PACB) reported revenue of $160.0M for fiscal 2025.
What is Pacific Biosciences of California's annual revenue history?
Pacific Biosciences of California's annual revenue by fiscal year: 2020: $78.9M; 2021: $130.5M; 2022: $128.3M; 2023: $200.5M; 2024: $154.0M; 2025: $160.0M.
What was Pacific Biosciences of California's net income in fiscal 2025?
Pacific Biosciences of California reported net income of -$546.4M for fiscal 2025.
What was Pacific Biosciences of California's earnings per share (EPS) in fiscal 2025?
Pacific Biosciences of California's diluted EPS was -$1.82 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Pacific Biosciences of California generate in fiscal 2025?
Pacific Biosciences of California generated -$113.9M of free cash flow in fiscal 2025.
What was Pacific Biosciences of California's revenue last quarter?
In its most recent reported quarter (2026 Q2), Pacific Biosciences of California reported revenue of $39.0M.
How much debt does Pacific Biosciences of California have?
Pacific Biosciences of California reported $645.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Pacific Biosciences of California are outstanding?
Pacific Biosciences of California reported a weighted average of 310.7 million basic shares outstanding in 2026 Q2.
What is Pacific Biosciences of California's market cap?
Based on its latest closing price, Pacific Biosciences of California (PACB) has a market capitalization of about $636.8M.
When does Pacific Biosciences of California's fiscal year end?
Pacific Biosciences of California's fiscal year end, as registered with the SEC, is December 31.
Where is Pacific Biosciences of California headquartered?
Pacific Biosciences of California lists its business address in Menlo Park, California in its SEC filings.